eGPA and local inflammation within the ENT area
Key facts
- Where
- Groningen, HollandiaSee the site
- Phase
- 4. fázis
Where in Hollandia
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Medisch Centrum Groningen
- Trial code
- EU 2023-508029-28-00
- Record updated
- 2024. február 2.
- Original description
In eGPA patients treatment with mepolizumab restores changes of the nasal microbiome healthy control phenotypeRead full original descriptionShow less
eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)
In eGPA patients treatment with mepolizumab restores changes of the nasal microbiome healthy control phenotype
Inclusion: >18 years of age; Able to give informed consent; In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan; In Severe asthma group: clinical diagnosis of asthma with FEV1 <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml); In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017); In GPA group: fulfilling the ACR/EULAR GPA criteria (Robson et al., 2022); In healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness.
Exclusion: In CRSwNP group: current use of asthma medication, eGPA; In healthy controls: use of immunosuppressive medication; concomitant use of dupilumab within 6 months of baseline visit; Unable to give informed consent; Active smoking < (less than) 6 months from baseline visit; Pregnant or breastfeeding woman; In healthy controls: chronic use of local anti-inflammtory agents; In healthy controls: use of antibiotics within the last month (before start study/screening/).